Endocrine Testing Market Analysis and Forecast to 2032: By Test Type (Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test

Endocrine Testing Market Analysis and Forecast to 2032: By Test Type (Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Others), Technology (Mass Spectroscopy, Immunoassay, Chromatography, Nucleic Acid Based), End-user (Hospitals, Commercial Laboratories, Ambulatory Care Centers, Others), and Region

The global Endocrine Testing Market was valued at USD 2.5 Billion in 2022 and it is anticipated to grow up to USD 8.8 Billion by 2032, at a CAGR of 13.5% during the forecast period.

Endocrine testing refers to the medical procedures conducted to measure the hormonal levels in the body and the diagnosis of hormone-related disorders. The testing aids in detecting an imbalance in the concentrations of hormones that may lead to the development of certain chronic conditions. These disorders are usually tested by fine-needle aspiration (FNA), ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI), positron emission test (PET), radioactive iodine scan (RAI) and venous sampling. The test results thus obtained can assist in determining the progression of the disorder and monitoring the effects of the treatment being provided to the patient.
Global Endocrine Testing Market Scope and Report Structure
[table id=707 /]
Market Trends and Drivers
The demand for endocrine testing is rising as there is increased health consciousness and a growing prevalence of lifestyle diseases among the adult individuals. This upsurge in awareness has contributed to increase of home healthcare and point-of-care (POC) devices with faster and efficient outputs. The home healthcare & POC devices are easy to operate and are cost effective alternatives targeting the adult as well the increasing geriatric population. According to the International Diabetes Federation, 537 million people are already living with diabetes in 2021, and this number is projected to shoot to 643 and 783 million by 2030 and 2045 respectively. These disease projections will directly impact the endocrine testing market and will result in a dramatic growth in the years to come.

With the growing diseased population, the number of tests employed for endocrinology has organically increased. This increase necessitated the need of many new technological advancements for faster and reliable results. For instance, the coupling of mass spectroscopy with liquid chromatography (LC/MS) or tandem mass spectrometry (MS/MS) provides results with better precision and accuracy. Moreover, companies like Agilent Technologies, Inc. are also focusing on developing new alternative technologies for analysis, such as use of LC-ICP-MS for more robust thyroid hormone testing. Such technological developments create huge opportunities for the existing & emerging players, and are expected to fuel the endocrine testing market growth tremendously.
Market Restraints and Challenges
The lack of skilled & trained professionals limits the accurate diagnosis restricts the market growth. As endocrine function testing requires sample handling & preparation stages, this necessitates skilled as well as technical expertise. The lack of technically strong personnel eventually limits the quality of endocrine testing and results in poor patient outcomes.
Global Endocrine Testing Market Segmental Overview
The report analyses the global Endocrine Testing Market based on test type, technology, end-user, and region.

Global Endocrine Testing Market by Test Type

On the basis of test type, it is segmented into Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, uteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, and Others. Among these, the human Chorionic Gonadotropin (hCG) hormone test dominated the endocrine testing market in 2021. High number of easy to use self-test pregnancy kits and need of quantitative estimation of hCG at hospitals or laboratories is contributing to the hCG test’s growth. Moreover, determination of hCG levels to detect abnormalities during different stages of pregnancy along with the growing number of fertile female population is also propelling the revenue generation of this segment. Furthermore, the role of hCG in treatment of infertility in both men & women will also drives the growth in endocrine testing market.

Additionally, TSH testing also generated significant revenue in 2021. TSH is a key regulator in immune response and is also associated in maintaining multiple hormone levels such as progesterone, hCG among others within the human body. These afore-mentioned roles of TSH along with prevalence of thyroid ailments such as cancer drives the market growth for TSH testing. As per Cancer.Net, it is estimated that in 2022 more than 43,500 adults will be diagnosed with thyroid cancer in the U.S.

Global Endocrine Testing Market by Technology

By technology, the industry is classified into Mass Spectroscopy, Immunoassay, Chromatography, and Nucleic Acid Based. In 2021, immunoassay based detection techniques generated a significant revenue of USD xx million in the endocrine testing market. This is due to the presence of multiple instruments and analyzers which uses different types of immunoassay technologies for detection. Also, the presence of immunoassay based tests panel for endocrine and reproductive function offered by many key players further contributes to the highest revenue generation of the segment.

On the contrary, owing to the advancements in technology since past few years, novel methods have been developed for hormone tests. Methods such as mass spectroscopy, chromatography, and nucleic acid based detection methods are taking over and providing accurate and precise results with a shorter turnaround time for endocrine testing panels. Furthermore, coupling of methods such as mass spectrometry with liquid chromatography offers consistent results and overcomes the drawbacks of traditional methods such as cross-reactivity.

Global Endocrine Testing Market by End-user

By End-User, Endocrine Testing has been segmented into Hospitals, Commercial Laboratories, Ambulatory Care Centers, and Others. Based on end-user, commercial laboratories held the largest market share of xx% in 2022. The availability of variety of tests panels and feasibility of at home collection services is boosting the revenue generation of this segment. Furthermore, commercial laboratories are also expected to observe the fastest growth in forthcoming years. This can be considered due to the growing health consciousness among individuals and the continuous endocrine testing to monitor existing disease and control the predisposed hereditary conditions. Also, the availability of reports over digital platforms by these commercial settings furthers their growth trajectory. For example, Laboratory Corporation of America Holdings or LabCorp, a U.S. based diagnostics company in February 2022 launched a digital portal allowing online orderings of tests and subsequently in April 2022, the company also launched a diagnostic test collection services at home.
Geographical Analysis of Global Endocrine Testing Market
Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America held the largest market share in the endocrine testing market with a share of 45.34% in 2021. This can be attributed to factors such as the high number of diabetic and obese population, affordable & accessible options due to presence of reimbursing bodies, government funding initiatives for the betterment of healthcare settings, as well as the availability of multiple diagnostic companies. For example, the American Thyroid Association, an organization dedicated to support research for treatment of thyroid diseases has funded over USD 2.8 million across 105 grants since the inception of its funding program. Additionally, the presence of key players in this region drives the competition and results in multiple product offerings in the endocrine testing market.
Major Players in the Global Catamaran Market
The key players in the Endocrine Testing Market  are  as Abbott Laboratories; AB Sciex; Agilent Technologies Inc.; bioMerieux SA, Bio-Rad Laboratories; DiaSorin S.p.A.; F.Hoffmann-La Roche Ltd; Laboratory Corporation of America Holdings; Quest Diagnostics Incorporated; and Ortho Clinical Diagnostics; among others.
COVID-19 Impact:
The endocrine testing market observed a moderate growth in the beginning of COVID-19 pandemic due to the widespread testing for detection of the SARS-CoV2 and research centered towards development of tools for detection. As a result, there was a substantial decrease in endocrine testing and research activities, furthermore closure of laboratories added to reduction in testing. However, the aim towards understanding the COVID-19 infection and the known role of thyroid hormone in immune response regulation led the researchers to study thyroid function in COVID-19 patients. For instance, researchers from Indonesia published in an article in October 2021, that they conducted a meta-analysis study by including 31,339 patients from 21 studies. In their systemic review, the researchers came to a conclusion that the risk of COVID-19 increased in patients with age & thyroid abnormalities and even resulted in poor treatment outcomes. This understanding revived the routine endocrine testing over the last year due to long-terms effects of COVID-19 infection in the survivors and is even expected to advance the market during forecasted period..
Recent Developments:

In April 2022, the LabCorp, launched a diagnostic test collection services at home.
In February 2022, Laboratory Corporation of America Holdings or LabCorp, a U.S. based diagnostics company launched a digital portal allowing online orderings of tests.
In August 2020, DiaSorin S.p.A announced that it has launched, LIAISON Testosterone xt test with CE marking. This test will be compatible with the company’s instrument, LIAISON XL for endocrine assay development to detect hypogonadism as well as hyperandrogenism. This launch also furthered DiaSorin’s existing endocrine and fertility panel of tests. Such initiatives will keep driving the endocrine testing market and increase the market competition.



Frequently Asked Questions
Q1. How big is the Catamaran market?

Ans. The global Endocrine Testing Market was valued at USD 2.5 Billion in 2022 and it is anticipated to grow up to USD 8.8 Billion by 2032, at a CAGR of 13.5% during the forecast period.

Q2. What is the Endocrine Testing Market growth rate?

Ans. The growth rate of the Endocrine Testing Market is 13.5%

Q3. Which region holds a major market share for the market?

Ans. North America holds a major market share of the Endocrine Testing Market in 2021.

Q4. Which segment accounted for the largest Endocrine Testing Market share?

Ans. By end-user, the Hospitals segment accounted for the largest Endocrine Testing Market share.

Q5. Who are the key players in the kidney stones management market?

Ans. The global Endocrine Testing Market report includes players such as Abbott Laboratories; AB Sciex; Agilent Technologies Inc.; bioMerieux SA, Bio-Rad Laboratories; DiaSorin S.p.A.; F.Hoffmann-La Roche Ltd; Laboratory Corporation of America Holdings; Quest Diagnostics Incorporated; and Ortho Clinical Diagnostics; among others.

Q6. What are the factors driving the Endocrine Testing Market growth?

Ans. The major factors driving the growth of the market are increasing research activities and rapid technological developments caused launch of multiple detection tests as well as novel products by life science companies.

Q7. What are the key growth strategies of Endocrine Testing Market players?

Ans. The key growth strategies of Endocrine Testing Market players are product launch and product approval.

Q8. Which region will provide more business opportunities for the Endocrine Testing Market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the Endocrine Testing Market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.